TY  - JOUR
AU  - Slamon, Dennis J
AU  - Neven, Patrick
AU  - Chia, Stephen
AU  - Fasching, Peter A
AU  - De Laurentiis, Michelino
AU  - Im, Seock-Ah
AU  - Petrakova, Katarina
AU  - Bianchi, Giulia V
AU  - Esteva, Francisco J
AU  - Martín, Miguel
AU  - Nusch, Arnd
AU  - Sonke, Gabe S
AU  - De la Cruz-Merino, Luis
AU  - Beck, J Thaddeus
AU  - Pivot, Xavier
AU  - Sondhi, Manu
AU  - Wang, Yingbo
AU  - Chakravartty, Arunava
AU  - Rodriguez-Lorenc, Karen
AU  - Taran, Tetiana
AU  - Jerusalem, Guy
PY  - 2019
DO  - 10.1056/NEJMoa1911149
UR  - http://hdl.handle.net/10668/14815
T2  - The New England journal of medicine
AB  - In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal growth factor...
LA  - en
KW  - Aged
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Drug Administration Schedule
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Postmenopause
KW  - Progression-Free Survival
KW  - Purines
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
TI  - Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
TY  - research article
VL  - 382
ER  -